TABLE 2.
Outcomes at 90 days by baseline SBP
| SBP (mmHg) | ||||
| Outcome | <120 | 120–139 | ≥140 | P value |
| Death or dependency (mRSa 3–6) | 296/669b (44.2) | 778/2084b (37.3) | 2746/6986b (39.3) | 0.0060 |
| Disability (mRSa 3–5) | 228/669 (34.1) | 607/2084 (29.1) | 2189/6986b(31.3) | 0.0349 |
| Death | 68/669 (8.7) | 171/2084 (7.3) | 557/6986 (7.2) | 0.3308 |
| SAE | 138/795c (17.4) | 303/2393c (12.7) | 1098/7895c (13.9) | 0.0040 |
| Recurrent stroke | 43/795 (5.4) | 104/2393 (4.4) | 380/7895 (4.8) | 0.4289 |
| Cardiac or other vascular events | 26/795 (3.3) | 40/2393 (1.7) | 169/7895 (2.1) | 0.0247 |
| Pneumonia | 23/795 (2.9) | 54/2393 (2.3) | 215/7895 (2.7) | 0.4103 |
| Other infection | 11/795 (1.8) | 28/2393 (1.2) | 79/7895 (1.0) | 0.1326 |
| Other SAE | 28/795 (3.5) | 60/2393 (2.5) | 197/7895 (2.5) | 0.2134 |
Data are n/N (%); P value from chi-squared test. mRS, modified Rankin scale; SAE, serious adverse event.
a
The mRS represents a global, seven-level assessment of disability, in which scores of 0 or 1 indicate good function without or with symptoms but no disability, score of 2 indicates slight disability, scores of 3--5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death.
b
N is according to total number of patients at 90-day follow-up.
c
N is according to total number of patients randomized.